Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 217

1.

Distinct expression patterns of SULT2B1b in human prostate epithelium.

Yang J, Broman MM, Cooper PO, Lanman NA, Strand DW, Morrissey C, Ratliff TL.

Prostate. 2019 Aug;79(11):1256-1266. doi: 10.1002/pros.23829. Epub 2019 Jun 18.

PMID:
31212370
2.

Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNFα in Castration-Resistant Prostate Cancer.

Vickman RE, Yang J, Lanman NA, Cresswell GM, Zheng F, Zhang C, Doerge RW, Crist SA, Mesecar AD, Hu CD, Ratliff TL.

Mol Cancer Res. 2019 Jun;17(6):1253-1263. doi: 10.1158/1541-7786.MCR-18-1054. Epub 2019 Mar 1.

PMID:
30824526
3.

Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer.

Nikhil K, Chang L, Viccaro K, Jacobsen M, McGuire C, Satapathy SR, Tandiary M, Broman MM, Cresswell G, He YJ, Sandusky GE, Ratliff TL, Chowdhury D, Shah K.

Cancer Lett. 2019 Apr 28;448:182-196. doi: 10.1016/j.canlet.2019.01.035. Epub 2019 Feb 1.

PMID:
30716360
4.

Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy.

Orillion A, Damayanti NP, Shen L, Adelaiye-Ogala R, Affronti H, Elbanna M, Chintala S, Ciesielski M, Fontana L, Kao C, Elzey BD, Ratliff TL, Nelson DE, Smiraglia D, Abrams SI, Pili R.

Clin Cancer Res. 2018 Dec 15;24(24):6383-6395. doi: 10.1158/1078-0432.CCR-18-0980. Epub 2018 Sep 6.

PMID:
30190370
5.

Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies.

Sommer BC, Dhawan D, Ratliff TL, Knapp DW.

Bladder Cancer. 2018 Apr 26;4(2):149-159. doi: 10.3233/BLC-170145. Review.

6.

Cholesterol Esterification Inhibition Suppresses Prostate Cancer Metastasis by Impairing the Wnt/β-catenin Pathway.

Lee HJ, Li J, Vickman RE, Li J, Liu R, Durkes AC, Elzey BD, Yue S, Liu X, Ratliff TL, Cheng JX.

Mol Cancer Res. 2018 Jun;16(6):974-985. doi: 10.1158/1541-7786.MCR-17-0665. Epub 2018 Mar 15.

7.

Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation.

Goode KM, Petrov DP, Vickman RE, Crist SA, Pascuzzi PE, Ratliff TL, Davisson VJ, Hazbun TR.

Biochim Biophys Acta Gen Subj. 2017 Aug;1861(8):1992-2006. doi: 10.1016/j.bbagen.2017.05.006. Epub 2017 May 8.

8.

Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs.

Fulkerson CM, Dhawan D, Ratliff TL, Hahn NM, Knapp DW.

Int J Genomics. 2017;2017:6589529. doi: 10.1155/2017/6589529. Epub 2017 Apr 9. Review.

9.

Targeting and Internalization of Liposomes by Bladder Tumor Cells Using a Fibronectin Attachment Protein-Derived Peptide-Lipopolymer Conjugate.

Lee Y, Kischuk E, Crist S, Ratliff TL, Thompson DH.

Bioconjug Chem. 2017 May 17;28(5):1481-1490. doi: 10.1021/acs.bioconjchem.7b00153. Epub 2017 May 5.

10.

Pten is necessary for the quiescence and maintenance of adult muscle stem cells.

Yue F, Bi P, Wang C, Shan T, Nie Y, Ratliff TL, Gavin TP, Kuang S.

Nat Commun. 2017 Jan 17;8:14328. doi: 10.1038/ncomms14328.

11.

Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.

Li J, Wang R, Kong Y, Broman MM, Carlock C, Chen L, Li Z, Farah E, Ratliff TL, Liu X.

Mol Cancer Ther. 2017 Mar;16(3):469-479. doi: 10.1158/1535-7163.MCT-16-0361. Epub 2017 Jan 9.

12.

Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device.

Huang W, Chang CL, Brault ND, Gur O, Wang Z, Jalal SI, Low PS, Ratliff TL, Pili R, Savran CA.

Lab Chip. 2017 Jan 31;17(3):415-428. doi: 10.1039/c6lc01279e.

PMID:
28054089
13.

Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.

Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, DeKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC.

J Urol. 2017 Feb;197(2S):S200-S207. doi: 10.1016/j.juro.2016.10.073. Epub 2016 Dec 22.

PMID:
28012755
14.

Novel Use of Folate-Targeted Intraoperative Fluorescence, OTL38, in Robot-Assisted Laparoscopic Partial Nephrectomy: Report of the First Three Cases.

Shum CF, Bahler CD, Low PS, Ratliff TL, Kheyfets SV, Natarajan JP, Sandusky GE, Sundaram CP.

J Endourol Case Rep. 2016 Nov 1;2(1):189-197. eCollection 2016.

15.

Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.

Deng X, Shao G, Zhang HT, Li C, Zhang D, Cheng L, Elzey BD, Pili R, Ratliff TL, Huang J, Hu CD.

Oncogene. 2017 Mar 2;36(9):1223-1231. doi: 10.1038/onc.2016.287. Epub 2016 Aug 22.

16.

Cholesterol Sulfonation Enzyme, SULT2B1b, Modulates AR and Cell Growth Properties in Prostate Cancer.

Vickman RE, Crist SA, Kerian K, Eberlin L, Cooks RG, Burcham GN, Buhman KK, Hu CD, Mesecar AD, Cheng L, Ratliff TL.

Mol Cancer Res. 2016 Sep;14(9):776-86. doi: 10.1158/1541-7786.MCR-16-0137. Epub 2016 Jun 24.

17.

Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer.

Li J, Gu D, Lee SS, Song B, Bandyopadhyay S, Chen S, Konieczny SF, Ratliff TL, Liu X, Xie J, Cheng JX.

Oncogene. 2016 Dec 15;35(50):6378-6388. doi: 10.1038/onc.2016.168. Epub 2016 May 2.

18.

Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity.

Cimen Bozkus C, Elzey BD, Crist SA, Ellies LG, Ratliff TL.

J Immunol. 2015 Dec 1;195(11):5237-50. doi: 10.4049/jimmunol.1500959. Epub 2015 Oct 21.

19.

Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.

Li J, Karki A, Hodges KB, Ahmad N, Zoubeidi A, Strebhardt K, Ratliff TL, Konieczny SF, Liu X.

Mol Cell Biol. 2015 Dec;35(24):4185-98. doi: 10.1128/MCB.00825-15. Epub 2015 Oct 5.

20.

Characterization of autoimmune inflammation induced prostate stem cell expansion.

Wang HH, Wang L, Jerde TJ, Chan BD, Savran CA, Burcham GN, Crist S, Ratliff TL.

Prostate. 2015 Oct;75(14):1620-31. doi: 10.1002/pros.23043. Epub 2015 Jul 14.

21.

Expansion of prostate epithelial progenitor cells after inflammation of the mouse prostate.

Wang L, Zoetemelk M, Chitteti BR, Ratliff TL, Myers JD, Srour EF, Broxmeyer H, Jerde TJ.

Am J Physiol Renal Physiol. 2015 Jun 15;308(12):F1421-30. doi: 10.1152/ajprenal.00488.2014. Epub 2015 Apr 29.

22.

Avasimibe encapsulated in human serum albumin blocks cholesterol esterification for selective cancer treatment.

Lee SS, Li J, Tai JN, Ratliff TL, Park K, Cheng JX.

ACS Nano. 2015 Mar 24;9(3):2420-32. doi: 10.1021/nn504025a. Epub 2015 Feb 16.

23.

Impact of prostate inflammation on lesion development in the POET3(+)Pten(+/-) mouse model of prostate carcinogenesis.

Burcham GN, Cresswell GM, Snyder PW, Chen L, Liu X, Crist SA, Henry MD, Ratliff TL.

Am J Pathol. 2014 Dec;184(12):3176-91. doi: 10.1016/j.ajpath.2014.08.021. Epub 2014 Nov 22.

24.

Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness.

Yue S, Li J, Lee SY, Lee HJ, Shao T, Song B, Cheng L, Masterson TA, Liu X, Ratliff TL, Cheng JX.

Cell Metab. 2014 Mar 4;19(3):393-406. doi: 10.1016/j.cmet.2014.01.019.

25.

Use of graphene as protection film in biological environments.

Zhang W, Lee S, McNear KL, Chung TF, Lee S, Lee K, Crist SA, Ratliff TL, Zhong Z, Chen YP, Yang C.

Sci Rep. 2014 Feb 14;4:4097. doi: 10.1038/srep04097.

26.

Early growth response-1 (EGR-1) and nuclear factor of activated T cells (NFAT) cooperate to mediate CD40L expression in megakaryocytes and platelets.

Crist SA, Elzey BD, Ahmann MT, Ratliff TL.

J Biol Chem. 2013 Nov 22;288(47):33985-96. doi: 10.1074/jbc.M113.511881. Epub 2013 Oct 8.

27.

Fat dogs and coughing horses: K-12 programming for veterinary workforce development.

San Miguel SF, Carleton Parker L, Adedokun OA, Burgess WD, Cipriani Davis KS, Blossom TD, Schneider JL, Mennonno AM, Ruhl JD, Veatch JH, Wackerly AJ, Shin SY, Ratliff TL.

J Vet Med Educ. 2013 Winter;40(4):419-25. doi: 10.3138/jvme.0313-053R.

28.

Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer.

Song B, Liu XS, Rice SJ, Kuang S, Elzey BD, Konieczny SF, Ratliff TL, Hazbun T, Chiorean EG, Liu X.

Mol Cancer Ther. 2013 Jan;12(1):58-68. doi: 10.1158/1535-7163.MCT-12-0632. Epub 2012 Nov 27.

29.

Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer.

Chou CK, Schietinger A, Liggitt HD, Tan X, Funk S, Freeman GJ, Ratliff TL, Greenberg NM, Greenberg PD.

J Immunol. 2012 Oct 15;189(8):3936-46. doi: 10.4049/jimmunol.1201415. Epub 2012 Sep 14.

30.

α(V)β(6) integrin expression is induced in the POET and Pten(pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma.

Garlick DS, Li J, Sansoucy B, Wang T, Griffith L, Fitzgerald T, Butterfield J, Charbonneau B, Violette SM, Weinreb PH, Ratliff TL, Liao CP, Roy-Burman P, Vietri M, Lian JB, Stein GS, Altieri DC, Languino LR.

Am J Transl Res. 2012;4(2):165-74. Epub 2012 Apr 10.

31.

Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients.

Deng X, Elzey BD, Poulson JM, Morrison WB, Ko SC, Hahn NM, Ratliff TL, Hu CD.

Am J Cancer Res. 2011;1(7):834-44. Epub 2011 Aug 18.

32.

Fibronectin attachment protein from bacillus Calmette-Guerin as targeting agent for bladder tumor cells.

Coon BG, Crist S, González-Bonet AM, Kim HK, Sowa J, Thompson DH, Ratliff TL, Aguilar RC.

Int J Cancer. 2012 Aug 1;131(3):591-600. doi: 10.1002/ijc.26413. Epub 2011 Oct 20.

33.

Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation.

Liu XS, Song B, Elzey BD, Ratliff TL, Konieczny SF, Cheng L, Ahmad N, Liu X.

J Biol Chem. 2011 Oct 14;286(41):35795-800. doi: 10.1074/jbc.C111.269050. Epub 2011 Sep 2.

34.

Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer.

Svensson RU, Haverkamp JM, Thedens DR, Cohen MB, Ratliff TL, Henry MD.

Am J Pathol. 2011 Jul;179(1):502-12. doi: 10.1016/j.ajpath.2011.03.014. Epub 2011 May 7.

35.

An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate.

Haverkamp JM, Charbonneau B, Crist SA, Meyerholz DK, Cohen MB, Snyder PW, Svensson RU, Henry MD, Wang HH, Ratliff TL.

Prostate. 2011 Aug 1;71(11):1139-50. doi: 10.1002/pros.21327. Epub 2011 Jan 12.

36.

In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site.

Haverkamp JM, Crist SA, Elzey BD, Cimen C, Ratliff TL.

Eur J Immunol. 2011 Mar;41(3):749-59. doi: 10.1002/eji.201041069. Epub 2011 Feb 2.

37.

Platelet CD40L at the interface of adaptive immunity.

Elzey BD, Ratliff TL, Sowa JM, Crist SA.

Thromb Res. 2011 Mar;127(3):180-3. doi: 10.1016/j.thromres.2010.10.011. Epub 2010 Nov 13. Review.

38.

Cholesterol sulfate imaging in human prostate cancer tissue by desorption electrospray ionization mass spectrometry.

Eberlin LS, Dill AL, Costa AB, Ifa DR, Cheng L, Masterson T, Koch M, Ratliff TL, Cooks RG.

Anal Chem. 2010 May 1;82(9):3430-4. doi: 10.1021/ac9029482.

39.

Prostate specific antigen detection in patient sera by fluorescence-free BioCD protein array.

Wang X, Zhao M, Nolte DD, Ratliff TL.

Biosens Bioelectron. 2011 Jan 15;26(5):1871-5. doi: 10.1016/j.bios.2010.02.009. Epub 2010 Feb 20.

40.

Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.

Lubaroff DM, Konety BR, Link B, Gerstbrein J, Madsen T, Shannon M, Howard J, Paisley J, Boeglin D, Ratliff TL, Williams RD.

Clin Cancer Res. 2009 Dec 1;15(23):7375-80. doi: 10.1158/1078-0432.CCR-09-1910. Epub 2009 Nov 17.

41.

Platelet influence on T- and B-cell responses.

Sowa JM, Crist SA, Ratliff TL, Elzey BD.

Arch Immunol Ther Exp (Warsz). 2009 Jul-Aug;57(4):235-41. doi: 10.1007/s00005-009-0032-y. Epub 2009 Jul 4. Review.

PMID:
19578816
42.

Early microrecanalization of vas deferens following biodegradable graft implantation in bilaterally vasectomized rats.

Simons CM, De Young BR, Griffith TS, Ratliff TL, Jones E, Mallapragada SK, Wald M.

Asian J Androl. 2009 May;11(3):373-8. doi: 10.1038/aja.2008.8. Epub 2009 Apr 6.

43.

Platelet-derived CD154 enables T-cell priming and protection against Listeria monocytogenes challenge.

Elzey BD, Schmidt NW, Crist SA, Kresowik TP, Harty JT, Nieswandt B, Ratliff TL.

Blood. 2008 Apr 1;111(7):3684-91. doi: 10.1182/blood-2007-05-091728. Epub 2008 Feb 6.

44.

Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles.

Sprague DL, Elzey BD, Crist SA, Waldschmidt TJ, Jensen RJ, Ratliff TL.

Blood. 2008 May 15;111(10):5028-36. doi: 10.1182/blood-2007-06-097410. Epub 2008 Jan 15.

45.

Nuclear factor of activated T cells (NFAT) mediates CD154 expression in megakaryocytes.

Crist SA, Sprague DL, Ratliff TL.

Blood. 2008 Apr 1;111(7):3553-61. doi: 10.1182/blood-2007-05-088161. Epub 2008 Jan 7.

46.

Systemic and cell-specific immune response to laparoscopic and open nephrectomy in porcine model.

Duchene DA, Gallagher BL, Ratliff TL, Winfield HN.

J Endourol. 2008 Jan;22(1):113-20. doi: 10.1089/end.2007.9859.

PMID:
18177243
47.
48.

Involvement of growth factors in the process of post-vasectomy micro-recanalization.

Stahl BC, Ratliff TL, De Young BR, Wald M.

J Urol. 2008 Jan;179(1):376-80. Epub 2007 Nov 19.

PMID:
18006005
49.

Prostate inflammation and its potential impact on prostate cancer: a current review.

Haverkamp J, Charbonneau B, Ratliff TL.

J Cell Biochem. 2008 Apr 1;103(5):1344-53. Review.

PMID:
17955503
50.

The role of platelet CD154 in the modulation in adaptive immunity.

Sprague DL, Sowa JM, Elzey BD, Ratliff TL.

Immunol Res. 2007;39(1-3):185-93. Review.

PMID:
17917065

Supplemental Content

Loading ...
Support Center